IMPACT Medicom
We are a medical communications company with a passion for developing high-quality content. We write & design content for healthcare professionals and patients in a variety of therapeutic areas. If you like our podcast, please take the time to rate it and subscribe. See our website for more information, video capsules, and podcasts at: https://www.impactmedicom.com.
Episodes
67 episodes
Integrating Non-Covalent BTK Inhibitors in CLL: Navigating a Rapidly Evolving Treatment Landscape
In this podcast episode, Dr. Versha Banerji discusses the role of non-covalent BTK inhibitors for the treatment of CLL. Our Guest:Dr. Versha Banerji is a Clinician Scientist at CancerCare Manitoba and Senior Scientist at the Re...
•
17:37
Highlights from EHA 2024 - Updates on the Treatment of CLL
In this podcast episode, three of Canada’s top hematologists discuss data on the treatment of CLL presented at the European Hematology Association (or EHA) meeting in Madrid, Spain. The discussion involves an analysis of the data from 6 oral pr...
•
42:13
LIVE FROM EHA 2024 - Sonrotoclax plus Zanubrutinib in R/R CLL
In this episode of our podcast, recorded at the European Hematology Association (EHA) meeting in Madrid, Spain, we discuss updated results of the BGB-11417-101 trial with Dr. Stephen Opat. The BGB-11417-101 trial examined the efficacy and...
•
16:33
Cutting Edge Advances in the Treatment of Lung Cancer
In this episode, Dr. Barbara Melosky discusses cutting edge approaches to the treatment of Lung Cancer, including the use of artificial intelligence and novel therapeutic approaches such as cancer vaccines and new targeted therapies....
•
15:13
Precision Medicine Series: Ep15: Biomarkers in Upper GI Cancers
Welcome to our podcast episode on diagnostic, prognostic and predictive biomarkers for the treatment of upper GI cancers. In this episode, Dr Brezden-Masley (medical oncologist) and Dr Streutker (pathologist) discuss the latest biomarkers that ...
•
41:28
Management of Cutaneous Squamous Cell Carcinoma (cSCC): A Surgeon’s Perspective
In this video capsule, Dr. Mark Taylor discusses the surgical implications for the treatment of cSCC. This podcast episode is best viewed alongside the slides, which can be found in the video capsule version:
•
24:11
Immunotherapy for Kidney Transplant Patients with Skin Cancer
In this podcast episode, Dr. Evan Lipson discusses the use of immunotherapy for patients with skin cancer who have had a kidney transplant. Our guest:Dr. Lipson is an internationally-recognized skin cancer and immunotherapy speciali...
•
21:32
LIVE FROM ASH 2023: Isa-CYBORD induction chemotherapy in newly diagnosed, transplant eligible MM
In this podcast episode, Dr. Rami Kotb and Dr. Donna Reece discuss results of the CMRG Isa-CYBORD trial presented at the ASH 2023 meeting, and the implications of the results for Canadian clinical practice.Our Guests:Dr. Rami...
•
16:58
Live from ASH 2023: Dr Brown Discusses Updated Results of the ALPINE Trial in CLL
In this episode of our podcast, recorded at the American Society of Hematology (ASH) in San Diego, California, we discuss updated results of the ALPINE trial with Dr. Jennifer Brown. The ALPINE trial examined the efficacy and safety of za...
•
13:48
First-line treatment strategies for the management of la/mUC: S2 Ep 5 - ESMO 2023: Discussion on 1L LA/mUC
In this video capsule series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada.This fifth episode of the series was recorded live from ESMO 2023 with Dr. Tho...
•
Season 2
•
Episode 5
•
32:28
First Line la/mUC Evolving Treatment Strategies: S2 Ep 4 - Round Table Discussion
In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This second part of the series is based on a live webinar presented on Septembe...
•
26:41
First Line la/mUC Evolving Treatment Strategies: S2 Ep 3 - Case Discussion
In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This second part of the series is based on a live webinar presented on Septembe...
•
8:07
First Line la/mUC Evolving Treatment Strategies: S2 Ep 2 - First-Line Treatment
In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This second part of the series is based on a live webinar presented on Septembe...
•
14:52
First Line la/mUC Evolving Treatment Strategies: S2 Ep 1 - Unmet Needs
In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This second part of the series is based on a live webinar presented on Septembe...
•
Season 2
•
Episode 1
•
10:38
Precision Medicine Series: Ep14: External Quality Assurance in Biomarker Testing
Welcome to our podcast episode on external quality assurance (or eQA) for testing biomarkers in oncology, hosted by Anna Christofides. In this episode, we discuss with Dr. Emina Torlakovic, the use of eQA to aid in the improvement of biom...
•
39:04
Podcast Series - Urothelial Carcinoma: Management of Enfortumab Vedotin Adverse Events - EP4: Hyperglycemia
Welcome to our podcast series discussing treatment-related adverse events with enfortumab vedotin in the management of urothelial carcinoma. In this fourth episode, we discuss the management of hyperglycemia associated with enfortumab vedotin, ...
•
29:52
Podcast Series - Urothelial Carcinoma: Management of Enfortumab Vedotin Adverse Events - EP2: Skin Reactions
Welcome to our podcast series discussing treatment-related adverse events with enfortumab vedotin in the management of locally advanced or metastatic urothelial carcinoma. In this second episode, we discuss the management of skin reactions asso...
•
30:08
Podcast Series - Urothelial Carcinoma: Management of Enfortumab Vedotin Adverse Events - EP1: Introduction to EV
Welcome to our podcast series discussing treatment-related adverse events with enfortumab vedotin in the management of locally advanced or metastatic urothelial carcinoma. In this first episode, we discuss the evolution of therapy from chemothe...
•
16:05
Podcast Series - Urothelial Carcinoma: Management of Enfortumab Vedotin Adverse Events - EP3: Peripheral Neuropathy
Welcome to our podcast series discussing treatment-related adverse events with enfortumab vedotin in the management of urothelial carcinoma. In this third episode, we discuss the management of peripheral neuroptathy associated with enfortumab v...
•
22:47
Live from CCOLD - Treatment of CLL
In this episode of our podcast, recorded at the Canadian Conference on Lymphoproliferative Diseases (CCOLD) in Banff, Alberta, we discuss the latest updates in the treatment of CLL with Dr. Laurie Sehn, Dr. Matthew Davies, and Dr. Constantine T...
•
30:40
Live from CCOLD: Dr Davids Discusses the ALPINE Trial in CLL
In this episode of our podcast, recorded at the Canadian Conference on Lymphoproliferative Diseases (CCOLD) in Banff, Alberta, we discuss the results of the ALPINE trial with Dr. Matthew Davies. The ALPINE trial examined the efficacy and safety...
•
17:05
Precision Medicine Series: Ep13: Biomarkers in Endometrial Cancer
Welcome to our 13th podcast episode in the Precision Medicine Series. In this episode, hosted by Anna Christofides, we discuss diagnostic, prognostic and predictive biomarkers for the treatment of endometrial cancer. Our ...
•
35:53
Highlights from ASH: Canadian Perspective on the ALPINE Trial in CLL
Live From ASH, New Orleans:In this very special episode of our podcast, we discuss the results of the ALPINE trial with Dr. Laurie Sehn, following the dissemination of the results during the late breaking abstract session at the Amer...
•
15:19
ASH Highlights - ALPINE Trial Shows Improved Efficacy and Safety Profile of Zanubrutinib vs Ibrutinib in CLL
Live From ASH, New Orleans:In this episode, Dr. Jennifer Brown discusses results of the phase 3 ALPINE trial, presented as a late breaking abstract at the American Society of Hematology (ASH) meeting 2022 in New Orleans, LA. ...
•
14:34